| INTRODUCTION
Use of hydroxyethyl starch (HES) solutions is controversial in human medicine because the use of these fluids may be associated not only with acute kidney injury but also with impaired coagulation. 1, 2 The coagulopathy associated with HES solutions may involve several mechanisms, including: (1) inhibition of the formation of the fibrin network because of binding and inactivation of factor VIII and von
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Willebrand's factor (vWF); (2) . It has been speculated that dogs breakdown and eliminate HES solutions more rapidly than humans because of a higher activity of plasma alpha amylase. 5 Because TS is more rapidly cleared from the circulation than previous generations of HES, direct inhibition of factor VIII and vWF could be minimized and the negative effects of this colloid on coagulation might be lessened. 6 Tetrastarch may induce a transient hypocoagulable state in dogs. 7, 8 Results of a study showed that a large volume of TS (40 mL/ kg), compared to an equal volume of physiological saline, impaired coagulation in healthy and endotoxemic dogs. 7 In anesthetized normovolemic dogs, a 15 mL/kg bolus of TS diluted in either physiological saline or balanced electrolyte solution transiently impaired primary (evaluated by a platelet function analyzer) and secondary (assessed by rotational thromboelastometry [ROTEM]) hemostasis in relation to the same volume of physiological saline. 8 The authors concluded that the coagulopathy induced by TS was short-lived, but the duration of these effects could not be fully clarified because hemostasis was assessed 5 minutes and 3 hours after fluid administration. 8 Although these studies showed that coagulation can be impaired by TS, the clinical application of these findings is not clear because TS was compared to equal volumes of isotonic crystalloids. The volume expansion efficiency (ratio of plasma volume expansion to the volume of infused fluid) of TS far exceeds that achieved by isotonic crystalloids. 9, 10 Therefore, TS likely will cause dilutional coagulopathy if compared to equal volumes of isotonic crystalloids. The recommended volume of isotonic crystalloids for volume replacement (VR) after acute hemorrhage is at least 3 times the volume of shed blood. 9, 10 Because the volume expansion efficiency of TS is approximately 1:1, the volume of shed blood can be replaced by the same volume of TS. 9, 10 Our study aimed to compare the effects of VR with lactated
Ringer's solution (LRS) or TS, administered at a ratio of 3:1 and 1:1 of shed blood, respectively, on coagulation (primary and secondary hemostasis) in hemorrhaged dogs. healthy based on physical and laboratory investigations (CBC, serum biochemistry, urinalysis, venous blood gas analysis and electrolytes) that were within normal ranges. After the end of the study, all animals were adopted by private owners.
| MATERIAL AND METHODS

| Animals
| Study design
This prospective, crossover, opportunistic study was carried out in conjunction with another study that aimed to evaluate the effects of VR with LRS or TS after hemorrhage on extravascular lung water and markers of acute kidney injury. 11 During phase 1, animals were anesthetized for data collection without any intervention (control treatment). After a 2-week washout interval, 2 other anesthetic episodes were carried out on the same animals (8-week washout intervals).
During each anesthetic episode, dogs were hemorrhaged and randomly assigned 12 to receive VR or LRS or TS at ratios of 3:1 and 1:1 of the amount of shed blood (LRS and TS treatments; phase 2). After a 2-hour equilibration period, hematocrit, platelet count, buccal mucosal bleeding time (BMBT), prothrombin time (PT), activated partial thromboplastin time (aPTT), and ROTEM assays were performed at baseline (BL). After BL, animals were hemorrhaged. The volume of shed blood was determined using a formula that estimates the volume of blood that could theoretically be withdrawn from an individual to decrease the hematocrit to a predefined target value after VR. 13 The amount of shed blood was calculated with the aim to decrease the hematocrit to 33%. This blood volume was removed dur- Analyzer, IDDEX, Westbrook, ME).
| Experimental protocol and variables monitored
ing
| Rotational thromboelastometry
The viscoelastic properties of the blood clot were evaluated by ROTEM (ROTEM delta, Tem International GmbH, Munich, Germany)
analysis. Citrated blood (300 μL) samples were added to 2 cuvettes.
After blood samples were recalcified with 20 μL of calcium chloride 
| Data analysis
Using commercial statistical software (Prism 6.02, GraphPad, San Diego, CA), normality of data distribution was verified by a Kolmogorov-Smirnov test. Buccal mucosal bleeding time, PT, aPTT, and CT ex-TEM were asymmetrically distributed and were log transformed before analysis. A paired t test was used to compare the total amount of blood withdrawn in the LRS and TS treatment groups.
Comparisons among treatment groups were performed by a 2-way ANOVA for repeated measures by both factors (time and treatment) followed by post hoc comparisons among treatment groups using a Tukey's test adjusted for the repeated measure design. For all variables, the significance level was set at P < 0.05.
3 | RESULTS 3.1 | Effects of LRS and TS on hematocrit, platelet count, BMBT, PT, and aPTT (Table 1) The total volume of blood removed did not differ between LRS and TS treatments (25 AE 7 and 23 AE 4 mL/kg, respectively). The volumes of LRS and TS infused for VR were 75 AE 14 and 23 AE 4 mL/kg (P ≤ 0.0001).
The hematocrit decreased in comparison to controls from 0.5 to 24 hours after VR with LRS (P ≤ 0.0001-0.02) and TS (P ≤ 0.0001-0.001; Table 1 ). Hematocrit was significantly higher 24 hours after VR with TS than with LRS (P = 0.02).
Platelet (Table 2) The CFT ex-TEM and CFT in-TEM were significantly higher than controls from 0.5 to 4 hours after LRS (P ≤ 0.0001-0.01) and from 0. shown that TS administration after hemorrhagic shock does not alter primary hemostasis (ie, platelet function) beyond a dilutional effect in dogs. 18 Contrasting with large molecular weight HES solutions, TS has little impact on platelet aggregation in dogs and humans. 16, 18, 19 Although the activity of vWF and platelet aggregation were not evaluated in our study, primary hemostasis was clinically unaffected by either fluid because BMBT, which qualitatively evaluates platelet function (ie, ability to create an effective platelet plug), did not differ between the LRS and TS groups, and remained
| Effects of LRS and TS on ROTEM assays
within reference values for the species.
An increase in aPTT with normal PT might reflect a defect in fac- The small number of animals in our study raises the concern that there could have been a lack of power to show more subtle differences between treatments. Because of the opportunistic nature of the present study, which was carried out in conjunction with another trial, a sample size of 6 animals was estimated based on expected differences in extravascular lung water. 11 Another shortcoming of the study reported here is the fact that not all variables were similar between treatment groups before hemorrhage. Baseline MCF ex-TEM was significantly lower in the LRS treatment group compared to controls (62 AE 2.4 versus 57.8 AE 4.7 mm, P = 0.01), and this difference could have biased subsequent comparisons between the LRS treatment and the other treatment groups.
Although this difference could suggest that the washout intervals between experiments that involved hemorrhage and VR (8 weeks)
might not have been long enough to completely eliminate a carryover effect, this interval far exceeds the period required by the bone marrow to restore the depleted cells after blood donation in dogs (10 days). 24 The difference in MCT ex-TEM was relatively small and might have been caused by type II error.
| CONCLUSIONS
The use of TS for VR after hemorrhage in healthy dogs does not appear to impair primary hemostasis. 
